Systemic therapy for metastatic renal cell carcinoma Journal Article
| Authors: | Kroog, G. S.; Motzer, R. J. |
| Article Title: | Systemic therapy for metastatic renal cell carcinoma |
| Abstract: | Renal cell cancer (RCC) is the most common form of cancer of the kidney and accounts for approximately 44,000 cases per year in the United States. Historically, only immunotherapy showed activity in metastatic RCC. The improved survival and quality of life for patients with metastatic RCC over the last several years are direct results of advances made in understanding the development of RCC. Three targeted therapies-sunitinib, sorafenib, and temsirolimus-have been approved for use in the United States recently. Current research is aimed at developing new drugs and combining available drugs to improve upon the responses and survival seen with approved single agents. |
| Keywords: | sorafenib; sunitinib; temsirolimus; renal cell cancer; targeted therapy; receptor; kidney cancer; tyrosine kinase inhibitor; solid tumors; interferon-alpha; factor; monoclonal-antibody; phase-iii trial; endothelial growth-factor; antitumor-activity; low-dose interleukin-2; active chemotherapy |
| Journal Title: | Urologic Clinics of North America |
| Volume: | 35 |
| Issue: | 4 |
| ISSN: | 0094-0143 |
| Publisher: | W.B. Saunders Co-Elsevier Inc. |
| Date Published: | 2008-11-01 |
| Start Page: | 687 |
| End Page: | 701 |
| Language: | English |
| ACCESSION: | WOS:000261693500016 |
| DOI: | 10.1016/j.ucl.2008.07.007 |
| PROVIDER: | wos |
| PUBMED: | 18992622 |
| Notes: | --- - Article - "Source: Wos" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work